Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives
and Recommendations

J 2022

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU et. al.

Basic information

Original name

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

Authors

BALIAKAS, Panagiotis (guarantor), Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ (203 Czech Republic, belonging to the institution), Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH and Kostas STAMATOPOULOS

Edition

HemaSphere, Philadelphia, Lippincott Williams & Wilkins, 2022, 2572-9241

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.600

RIV identification code

RIV/00216224:14110/22:00129675

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1097/HS9.0000000000000707

UT WoS

000776250000005

Keywords in English

Chronic Lymphocytic Leukemia; Cytogenetics

Abstract

V originále

Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.

Links

NU20-08-00314, research and development project

Name: Single cell analýza: moderní nástroj pro studium klonální evoluce u pacientů s chronickou lymfocytární leukémií s vysokým rizikem (Acronym: Single cell analysis of CLL cells)

Investor: Ministry of Health of the CR, Subprogram 1 - standard

NU21-08-00237, research and development project

Name: Pokročilé sekvenační metody pro analýzu strukturních přestaveb nádorového genomu

Investor: Ministry of Health of the CR, Advanced sequencing methods for deciphering structural variants in cancer genome, Subprogram 1 - standard

NV19-03-00091, research and development project

Name: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby

Investor: Ministry of Health of the CR

Citovat

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH and Kostas STAMATOPOULOS. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. HemaSphere. Philadelphia: Lippincott Williams & Wilkins, 2022, vol. 6, No 4, p. 1-7. ISSN 2572-9241. Available from: https://dx.doi.org/10.1097/HS9.0000000000000707.

@article{2211017,
   author = {Baliakas, Panagiotis and Espinet, Blanca and Mellink, Clemens and Jarošová, Marie and Athanasiadou, Anastasia and Ghia, Paolo and Kater, Arnon P and Oscier, David and Haferlach, Claudia and Stamatopoulos, Kostas},
   article_location = {Philadelphia},
   article_number = {4},
   doi = {http://dx.doi.org/10.1097/HS9.0000000000000707},
   keywords = {Chronic Lymphocytic Leukemia; Cytogenetics},
   language = {eng},
   issn = {2572-9241},
   journal = {HemaSphere},
   title = {Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations},
   url = {https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx},
   volume = {6},
   year = {2022}
}

TY  - JOUR
ID  - 2211017
AU  - Baliakas, Panagiotis - Espinet, Blanca - Mellink, Clemens - Jarošová, Marie - Athanasiadou, Anastasia - Ghia, Paolo - Kater, Arnon P - Oscier, David - Haferlach, Claudia - Stamatopoulos, Kostas
PY  - 2022
TI  - Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
JF  - HemaSphere
VL  - 6
IS  - 4
SP  - 1-7
EP  - 1-7
PB  - Lippincott Williams & Wilkins
SN  - 25729241
KW  - Chronic Lymphocytic Leukemia
KW  - Cytogenetics
UR  - https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx
N2  - Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
ER  -

BALIAKAS, Panagiotis, Blanca ESPINET, Clemens MELLINK, Marie JAROŠOVÁ, Anastasia ATHANASIADOU, Paolo GHIA, Arnon P KATER, David OSCIER, Claudia HAFERLACH and Kostas STAMATOPOULOS. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. \textit{HemaSphere}. Philadelphia: Lippincott Williams \&{} Wilkins, 2022, vol.~6, No~4, p.~1-7. ISSN~2572-9241. Available from: https://dx.doi.org/10.1097/HS9.0000000000000707.

Detailed Information on Publication Record